Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?

To: Biomaven who wrote (14624)	12/10/2004 12:39:19 PM
From: Sam Citron	Read Replies (1) \| Respond to of 52153

Peter, Is a drug discovery like R207910 mainly meaningful on humanitarian grounds, or does it have some potential to be a meaningful contributor to profits at JNJ? How would one begin to estimate its profit potential? Rifampin has been a standard for so long and is so cheap (generic). I have no idea what total worldwide sales are, or even where to obtain such data. R207910, I assume, would be free of generic competition for a significant period of time, but I suppose that drugs that tend to treat diseases of the poor tend not to be big money makers. Is such a perception correct? TIA, Sam